Apr 20, 2012 by Brian Orelli, PhDFor Sale, Just Not at That PriceHuman Genome Sciences rejects Glaxo's offer, but is open to a sale.
Apr 20, 2012 by Brian Orelli, PhDPartner Up or Get Passed UpDrug cocktails are the future of hepatitis C drugs.
Apr 19, 2012 by Brian Orelli, PhDThis Takeover Is Off the Table. Maybe.Has Roche walked away from Illumina, or is it bluffing?
Apr 18, 2012 by Brian Orelli, PhDA $5 Million Lottery TicketDepomed plans to submit a marketing application for Serada.
Apr 18, 2012 by Brian Orelli, PhDIntuitive Surgical Follows Buffett's AdviceManagement explains why it isn't buying shares.
Apr 17, 2012 by Brian Orelli, PhDYou'll Have to Hold This One for the DividendNot many other reasons to hold J&J in the short term right now.
Apr 16, 2012 by Brian Orelli, PhDThis Instant Double Is Still CheapEndocyte doubles on news that Merck licensed vintafolide.
Apr 13, 2012 by Brian Orelli, PhDIs Teva About to Tear Itself Apart?Teva considers dropping its entire branded drug segment.
Apr 13, 2012 by Brian Orelli, PhDIt's Fashionably Late, but This Biotech's Party Is Just StartingSeattle Genetics partners with Roche to develop a companion diagnostic for Adcetris.
Apr 13, 2012 by Brian Orelli, PhDMore Hair, Less Reason for ItMerck's baldness treatment Propecia has sexual side effects.
Apr 12, 2012 by Brian Orelli, PhDOops, Our Data Weren't That GoodTargacept revises its data for TC-6987 downward.
Apr 12, 2012 by Brian Orelli, PhDWhy Intuitive Surgical Is Right for Your IRAGrowth potential trumps riskiness for younger investors.
Apr 12, 2012 by Brian Orelli, PhDYou, Sir, Are No Apple (but We Still Want to Buy You)Roche insults Illumina, Lloyd Bentsen-style.
Apr 12, 2012 by Brian Orelli, PhDThis Biotech Buys a Generic LifelineAmgen buys KAI Pharmaceuticals to replace Sensipar.
Apr 11, 2012 by Brian Orelli, PhDWith Revenue Decimated, Is ViroPharma a Buy?ViroPharma is easier to value.
Apr 10, 2012 by Brian Orelli, PhDThis Billionaire Is Wasting Your MoneyIcahn's frivolous lawsuit against Amylin.
Apr 10, 2012 by Brian Orelli, PhDFDA Delay Points to Blockbuster ApprovalVIVUS' Qnexa delay is likely good news.
Apr 9, 2012 by Brian Orelli, PhDMaking Money Helping Alzheimer's ResearchersEli Lilly's Amyvid gets FDA approval.
Apr 5, 2012 by Brian Orelli, PhDDown 24%, but Not Nuked YetClevland BioLabs' funding is uncertain, but not unattainable.
